The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
NVL-330 features among the latest crop of industry projects newly into human trials.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.